What Is Epithalon?

Published August 2026 · Patriot Labs Research Team · ~12 min read

What Epithalon actually is

Epithalon — also written Epitalon or Epithalone — is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, abbreviated AEDG. Four residues, three peptide bonds, no ring systems, no unusual amino acids, no chemical modifications. Summing the residue masses and subtracting the water lost at each bond puts it around 390 Da, which makes it one of the smallest molecules routinely sold as a research peptide. For comparison, BPC-157 is fifteen residues and TB-500 material relates to a 43-residue parent.

The origin story matters, and it is usually told wrong. A 2025 review in the International Journal of Molecular Sciences states that Epitalon was synthesised based on the amino acid composition of Epithalamin — a bovine pineal gland extract — and was only afterwards identified within a pineal gland polypeptide complex solution. That ordering is worth holding onto. AEDG was not isolated as a natural signalling peptide and then characterised. It was constructed to represent the amino acid makeup of a crude glandular extract, and the biological reputation of the extract was then inherited by the four-residue molecule.

This distinction between Epithalamin and Epithalon runs through the entire evidence base and is the single most common source of confusion. Epithalamin is a crude polypeptide extract of bovine pineal glands — a mixture whose composition can vary between preparations. Epithalon is a single defined synthetic tetrapeptide. An Alzheimer's Drug Discovery Foundation review of both compounds makes the point directly: the mixed composition of the extract makes it difficult to work out which effects come from AEDG specifically. As you will see below, the cell-culture telomerase work used the synthetic peptide, while the long-term human mortality work used the extract. Those are not the same evidence base, and vendor summaries routinely merge them.

Both come from the same source: the laboratory of Vladimir Khavinson at the St Petersburg Institute of Bioregulation and Gerontology, which has produced work on short peptides and ageing for several decades. Epithalon sits inside a broader family of short peptides from that programme, alongside compounds such as Pinealon, and it is a standard entry in most surveys of peptides studied in an anti-ageing context.

The peptide bioregulator framework

You cannot read the Epithalon literature sensibly without understanding the theory it was generated inside, so it is worth laying out fairly before criticising it.

Khavinson's group proposes that very short peptides — roughly two to seven residues — function as an ancient class of signalling molecule that acts directly on the genome. In their 2021 systematic review in Molecules, these are framed as “cytomedines”: intercellular mediators that penetrate the cell nucleus and control genome function, binding DNA and histone proteins to modulate transcription. The claimed specificity is tissue-level — a peptide derived from a given organ is proposed to preferentially regulate genes relevant to that organ, which is why the family includes separate pineal, thymic, vascular and retinal peptides rather than one general-purpose compound.

The supporting evidence in that review is a particular kind. It includes gel electrophoresis and ethidium bromide displacement work showing tetrapeptides interacting with DNA, circular dichroism spectroscopy indicating sequence preferences among homopolymers, and computational modelling that identified a small subset of dipeptides with high selectivity for double-stranded DNA tetranucleotides. A companion 2016 paper in the Bulletin of Experimental Biology and Medicine built spatial models of nineteen peptide–DNA complexes by molecular docking, reporting that specific short peptides preferred specific four-base sequences. For AEDG itself, the 2021 review reports regulation of roughly 98 genes, including circadian markers, and binding to histone proteins.

Two honest observations follow. First, most of this is biophysics and in silico modelling rather than cell biology — docking a peptide onto a DNA model is a hypothesis-generating exercise, not a demonstration that the peptide reaches the nucleus at physiological exposure and changes transcription there. Second, the authors say the quiet part themselves: their 2021 review acknowledges there are very few studies in this area compared with DNA methylation or histone acetylation research, that precise promoter binding sites are difficult to identify for most peptides, and that mechanism specificity remains poorly characterised.

The framework is coherent and it is not obviously absurd. It is also not a mainstream, widely-replicated model of gene regulation. Outside this research programme, short peptides are not generally treated as direct transcriptional regulators, and the bioregulator concept has not been taken up as a standard mechanism in the wider molecular biology literature. Treat it as one group's working hypothesis with supporting data, not as established mechanism.

The telomerase claim, examined

This is why Epithalon is famous, so it deserves precision rather than summary.

Telomeres are repetitive sequences capping chromosome ends. They shorten with each round of somatic cell division because DNA polymerase cannot fully replicate the end of a linear template. Telomerase is the reverse transcriptase that adds those repeats back, and its catalytic subunit is TERT. In most differentiated human cells telomerase is off, and progressive telomere attrition eventually triggers replicative senescence — the Hayflick limit. That is the background against which the Epithalon results were reported.

The first paper is Khavinson, Bondarev and Butyugov, published in the Bulletin of Experimental Biology and Medicine in 2003. Adding Epithalon to telomerase-negative human fetal fibroblast cultures induced expression of the telomerase catalytic subunit, induced telomerase enzymatic activity, and produced telomere elongation. The authors attribute this to reactivation of the telomerase gene in somatic cells.

The second is the 2004 follow-up from the same laboratory, with Smirnova added. Primary pulmonary fibroblasts derived from a 24-week fetus lost proliferative potential at passage 34, with mean telomere size appreciably lower than at passage 10. Adding Epithalon to the ageing cultures induced telomere elongation to a length comparable with early passages, and the treated cells made ten additional divisions — reaching passage 44 — and continued dividing. The authors conclude that the peptide prolonged the vital cycle of normal human cells by overcoming the Hayflick limit.

Read carefully, those are the strongest results in the whole Epithalon file, and they are also narrower than the way they get repeated. The model is cultured human fetal fibroblasts — not adult tissue, not an intact organism. The endpoint is passage number and telomere length in a dish, not any organism-level outcome. And the finding is that a senescence barrier was bypassed, which the paper frames as a benefit; a cancer biologist reads the same sentence differently, and we return to that below.

The replication position is the part that matters most and is almost never stated. The Alzheimer's Drug Discovery Foundation's review of Epithalamin and Epithalon states plainly that there are no publications independently replicating these in vitro results. Twenty-plus years after publication, the central experimental claim behind the compound's entire reputation rests on the group that made it.

What the animal work showed

The most-cited rodent study is Anisimov, Khavinson, Popovich and colleagues in Biogerontology in 2003. Female outbred Swiss-derived SHR mice received monthly subcutaneous injection courses of either saline or Epitalon from three months of age until natural death, with 54 animals per group.

The results are more mixed than the summaries suggest. Mean lifespan was unchanged. The lifespan of the last 10% of survivors rose by 13.3%, and maximum lifespan rose by 12.3%. Chromosome aberrations in bone marrow cells fell by 17.1%. Total spontaneous tumour incidence showed no effect, though leukaemia development was inhibited roughly six-fold relative to controls.

Two things are worth drawing out. First, an effect on maximum but not mean lifespan is a specific and relatively modest signature — it says the tail of the survival curve moved, not that the average animal lived longer. Second, and importantly given the cancer discussion below, this study did not report an increase in total tumour incidence in treated animals. That is a real data point in the compound's favour and should be stated as such. It is one strain, one sex, one laboratory, and mice are not a strong model for human carcinogenesis over decades, but it is not nothing.

The ADDF review notes lifespan extension has also been reported in flies and rats, and adds that none of those results has been replicated by independent laboratories either.

The human mortality cohorts

Khavinson's group has published long-running human work reporting reduced mortality in elderly subjects, and these papers are the backbone of the compound's marketing. They deserve to be reported accurately, including their design.

Khavinson and Morozov, in Neuro Endocrinology Letters in 2003, followed 266 older adults for six to eight years, administering thymic (Thymalin) and pineal (Epithalamin) peptide preparations during the first two to three years. The paper reports reduced mortality across groups — roughly two-fold with the thymic preparation, roughly 1.6 to 1.8-fold with the pineal preparation, around 2.5-fold with both, and around four-fold in a subgroup treated annually across six years — alongside reductions in reported cardiovascular, respiratory and musculoskeletal disease incidence.

Korkushko, Khavinson, Shatilo and Antonyuk-Shcheglova, in the Bulletin of Experimental Biology and Medicine in 2006, describe a 12-year randomised study of epithalamine in elderly patients with coronary disease and accelerated cardiovascular ageing, added to standard therapy against a standard-therapy control. They report 28% lower mortality at 12 years, roughly two-fold reductions in cardiovascular mortality, and improvements in functional-age and exercise-tolerance measures.

Now the caveats, which are not minor.

The agent in both is Epithalamin, the crude bovine pineal extract — not the synthetic AEDG tetrapeptide. Whatever those cohorts show, they do not directly establish anything about Epithalon as a defined molecule. The ADDF review makes exactly this point about extract composition varying between preparations.

Every study in this file — preclinical and clinical — was conducted by Khavinson's group in Russia, and the ADDF review states the clinical mortality results have not been independently confirmed. Roughly half of the surrounding body of publications exists only in Russian, which is a practical barrier to external scrutiny on top of the structural one. Reporting standards in the accessible papers are thin by contemporary expectations: randomisation and allocation concealment procedures, blinding, pre-registration, statistical analysis plans and full baseline comparability data are not available at the level a modern trial report would provide. A 2026 review in Frontiers in Aging that discusses Epitalon sympathetically still describes it as unapproved, supported by small clinical studies, without long-term safety data and without Western randomised controlled trials.

None of this means the results are wrong. It means they are unverified in the specific sense that matters — nobody outside the originating group has reproduced them, and the reports do not contain enough methodological detail for a reader to assess them independently.

Claim by claim — and who published it

Laid out side by side, the pattern in the evidence base becomes obvious.

One laboratory, one country, one continuous research programme, across every row. That is the single most important fact about Epithalon, and it is the one most consistently omitted.

Why telomerase is a double-edged target

Longevity write-ups tend to treat “activates telomerase” as an unambiguous positive. Telomere biologists do not, and the reason is straightforward.

Telomerase is silent in most differentiated human cells, predominantly through transcriptional repression of the TERT gene. That silence is not an oversight. Progressive telomere shortening imposes a hard ceiling on how many times a somatic cell can divide, and when that ceiling is reached the cell enters replicative senescence — a permanent growth arrest. This is a tumour-suppressive mechanism: it caps the number of divisions available to a cell that has begun accumulating oncogenic mutations.

A tumour therefore has to solve the telomere problem to keep dividing. Yuan, Larsson and Xu, writing in Oncogene in 2019, report that TERT expression or telomerase activity is detectable in up to 90% of human primary cancers, and state that TERT and telomerase activation has been shown experimentally to be essential to cellular immortalisation and malignant transformation by stabilising telomere length and erasing the senescence barrier. A 2025 narrative review in Frontiers in Oncology gives the same figure from the other side — approximately 90% of human malignancies show considerable hTERT expression, despite telomerase being normally repressed in almost all somatic cells — and describes oncogenic cells as avoiding senescence and dividing indefinitely.

Put the two literatures next to each other and the tension is unavoidable. The 2004 Epithalon paper reports, as its headline finding, that treated human cells overcame the Hayflick limit and continued dividing. That is a description of the exact capability that oncology considers a prerequisite for malignant transformation. This does not mean Epithalon causes cancer — nothing in the retrieved literature demonstrates that, and the SHR mouse study reported no increase in total spontaneous tumour incidence. It means the mechanism being advertised as the compound's main attraction is the same mechanism the cancer field spends considerable effort trying to inhibit, and that a positive telomerase result is not self-evidently a good result.

This is also why telomerase-targeting therapeutics have overwhelmingly been developed as inhibitors rather than activators. The Frontiers in Oncology review discusses telomerase as a therapeutic target in oncology in the inhibition direction, noting for instance that the telomerase inhibitor imetelstat had serious adverse effects in children with recurrent central nervous system malignancies. The field's practical experience with this enzyme is as a target to shut down.

Anyone evaluating Epithalon should hold both halves at once: the reported in vitro telomerase effect is the reason it is interesting, and it is also the reason it warrants more caution than a compound with a bland mechanism, not less.

What the evidence does not establish

Stated plainly, because the marketing around this compound is unusually detached from the underlying papers.

It does not establish independent reproducibility. The ADDF review states that every preclinical and clinical study it discusses was conducted by Khavinson's group in Russia with no independent confirmation, and that no publications independently replicate the telomerase findings. A result that has stood unreplicated for two decades is not a settled result, in either direction.

It does not establish that the tetrapeptide is the active entity in the human data. The mortality cohorts used Epithalamin, a crude bovine pineal extract of variable composition. Attributing those outcomes to AEDG is an inference, not a finding.

It does not establish telomere effects in adult somatic tissue. The telomere data are from cultured human fetal fibroblasts. Fetal cells, culture conditions and passage-number endpoints do not extrapolate cleanly to differentiated adult tissue in an intact organism, where telomerase repression is under different regulatory pressure.

It does not establish a defined mechanism. The 2025 IJMS review lists a scattered set of reported activities — effects on melatonin synthesis, interleukin-2 mRNA levels, murine thymocyte mitogenic activity, and enhancement of several enzymes including telomerase — and states it remains uncertain whether these are the sole mechanisms of action. The same review notes that physico-chemical and structural investigation of the peptide is quite limited despite the volume of biological work, which is an unusual and telling asymmetry.

It does not establish long-term safety. The ADDF review notes two three-year trials reported no severe adverse events but concludes that a well-conducted Phase 1 safety study and independent validation are still needed, citing variability in extract composition and potential synthetic impurities. The 2026 Frontiers in Aging review states there are no long-term safety data and no Western randomised controlled trials. There is no long-horizon cancer surveillance data in humans for a compound whose selling point is telomerase induction.

It does not establish anything about human outcomes from any product sold on this site. Epithalon is not an approved drug and is stocked here for laboratory research only.

Bench and documentation notes

A four-residue peptide is chemically simple to make, which cuts both ways. Solid-phase synthesis of AEDG is short and high-yielding — see how peptides are made for the general process — so material is cheap and the synthesis is unlikely to be the failure point. The corollary is that a low price tells you nothing about identity or purity here, because the cost floor is low for anyone, including a supplier cutting corners. Analytical documentation carries the whole burden.

Read the certificate of analysis for mass confirmation as well as HPLC purity. For a peptide this small, mass spectrometry is a genuinely informative identity check: the expected mass is unambiguous, and any substitution or deletion in a four-residue sequence produces a large proportional shift. Purity by HPLC alone does not tell you that the correct four residues are present in the correct order.

Handling follows the standard rules for lyophilised material rather than anything peptide-specific — the storage guide and the degradation guide cover the relevant chemistry. Two features of this sequence are worth flagging for anyone designing a stability protocol: aspartate followed by glycine is a well-known site for isomerisation and succinimide-mediated backbone rearrangement in peptide chemistry, and the two adjacent acidic residues make the molecule strongly pH-sensitive in solution. If you are running anything longer than a same-day experiment, characterise your own solution stability rather than assuming it.

For anyone mapping the wider longevity peptide space, the adjacent guides are best peptides for anti-ageing, what is NAD+ for the metabolic and sirtuin-adjacent side of the field, and best peptides for cognition where several other short peptides from the same Russian programme appear. Pinealon is the closest catalogue neighbour, and it sits inside the same bioregulator framework, with the same replication caveats attached.

Frequently asked questions

What is Epithalon? A synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), also written Epitalon or Epithalone. The 2025 IJMS review describes it as having been synthesised based on the amino acid composition of Epithalamin, a bovine pineal gland extract, and later identified within a pineal polypeptide complex. It came out of Vladimir Khavinson's group in St Petersburg.

Did Epithalon really lengthen telomeres? In cell culture, in experiments published by one group. The 2003 paper reported induction of the telomerase catalytic subunit, telomerase activity and telomere elongation in telomerase-negative human fetal fibroblasts. The 2004 follow-up reported treated primary fetal pulmonary fibroblasts reaching passage 44 against passage 34 in controls. The ADDF review states there are no publications independently replicating those results.

Is Epithalon the same as Epithalamin? No, and conflating them is the most common error in write-ups on this compound. Epithalamin is a crude bovine pineal extract of variable composition. Epithalon is a single defined synthetic tetrapeptide. The cell-culture telomerase work used the peptide; the long-term human mortality cohorts used the extract.

What are peptide bioregulators? Khavinson's framework, in which short peptides of roughly two to seven residues act as signalling molecules that enter the nucleus and regulate transcription by interacting with DNA and histones, with tissue-specific preferences. The supporting work is largely molecular docking and biophysical assays. The authors' own 2021 review notes very few studies exist in the area and that precise promoter binding sites are hard to identify. It is not a mainstream model of gene regulation.

Why is telomerase activation considered a double-edged target? Because telomerase reactivation is a feature of most cancers. TERT expression or telomerase activity is detectable in up to 90% of human primary cancers, telomerase is silent in most differentiated human cells, and telomere shortening functions as a replicative senescence barrier that limits the divisions available to a damaged cell. Lifting that barrier is precisely what a tumour must accomplish, which is why most telomerase-targeting drug development has pursued inhibition rather than activation.

Does the animal data show increased cancer? Not in the study retrieved for this guide. The 2003 Biogerontology mouse study reported no effect on total spontaneous tumour incidence and roughly six-fold inhibition of leukaemia development, alongside a 12.3% increase in maximum lifespan with mean lifespan unchanged. That is one strain, one sex, one laboratory, and unreplicated.

Is Epithalon approved for human use? No. It is sold strictly for in-vitro research and laboratory use only. It is not an approved drug and is not intended for human or veterinary consumption. The 2026 Frontiers in Aging review describes it as unapproved, supported by small clinical studies, with no long-term safety data and no Western randomised controlled trials.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes peptide chemistry and published research in general terms; it is not medical advice, does not describe how to use any product, and the references cited do not constitute a product claim.